Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2007;110:865-872
© 2007 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Northen, A. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Northen, A. T.

ORIGINAL ARTICLES

Follow-up of Children Exposed In Utero to 17 {alpha}-Hydroxyprogesterone Caproate Compared With Placebo

Allison T. Northen, RN, BSN1, Gwendolyn S. Norman, RN, BSN, MPH2, Kristine Anderson, RN, BSN3, Lisa Moseley, RN4, Michelle DiVito, RN, MSN5, Margaret Cotroneo, RN, CCRC6, Melissa Swain, RN7, Sabine Bousleiman, RNC, MSN8, Francee Johnson, RN, BSN9, Karen Dorman, RN, MS10, Cynthia Milluzzi, RN, BSN11, Jo-Ann Tillinghast, RN, MSN12, Marcia Kerr, RN, CCRC13, Gail Mallett, BSN, CCRC14, Elizabeth Thom, PhD15, Susan Pagliaro16, Garland D. Anderson, MD17 for the National Institute of Child Health and Human Development (NICHD) Maternal–Fetal Medicine Units (MFMU) Network*

From the Departments of Obstetrics and Gynecology, 1Center for Women’s Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama; 2Wayne State University, Detroit, Michigan; 3University of Utah, Salt Lake City, Utah; 4University of Texas Southwestern Medical Center, Dallas, Texas; 5Drexel University, Philadelphia, Pennsylvania; 6University of Pittsburgh, Pittsburgh, Pennsylvania; 7Wake Forest University, Winston-Salem, North Carolina; 8Columbia University, New York, New York; 9Ohio State University, Columbus, Ohio; 10University of North Carolina, Chapel Hill, North Carolina; 11Case Western Reserve University, Cleveland, Ohio; 12Brown University, Providence, Rhode Island; 13University of Texas at Houston, Houston, Texas; 14Northwestern University, Chicago, Illinois; 15the George Washington University Biostatistics Center, Washington, DC; 16National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland; and 17the University of Texas Medical Branch, Galveston, Texas.

ABSTRACT

OBJECTIVE: To assess whether there are evident adverse effects of 17 {alpha}-hydroxyprogesterone caproate after in utero exposure.

METHODS: This study evaluated surviving children of mothers who participated in a multicenter placebo-controlled trial of weekly intramuscular 17 {alpha}-hydroxyprogesterone caproate, with a 2:1 allocation to 17 {alpha}-hydroxyprogesterone caproate and placebo, respectively. The guardian was interviewed about the child’s general health. Children underwent a physical examination and developmental screen with the Ages and Stages Questionnaire. Gender-specific roles were assessed with the Preschool Activities Inventory.

RESULTS: Of 348 eligible surviving children, 278 (80%) were available for evaluation (194 in the 17 {alpha}-hydroxyprogesterone caproate group and 84 in the placebo group). The mean age at follow-up was 48 months. No significant differences were seen in health status or physical examination, including genital anomalies, between 17 {alpha}-hydroxyprogesterone caproate and placebo children. Scores for gender-specific roles (Preschool Activities Inventory) were within the normal range and similar between 17 {alpha}-hydroxyprogesterone caproate and placebo groups.

CONCLUSION: 17 {alpha}-hydroxyprogesterone caproate seems to be safe for the fetus when administered in the second and third trimesters.

LEVEL OF EVIDENCE: II




This article has been cited by other articles:


Home page
 Obstet GynecolHome page
J. M. Dodd, V. J. Flenady, R. Cincotta, and C. A. Crowther
Progesterone for the Prevention of Preterm Birth: A Systematic Review
Obstet. Gynecol., July 1, 2008; 112(1): 127 - 134.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. M. O'Brien, M. Chandiramani, R. Tribe, A. Shennan, K. H. Nicolaides, E. Celik, E. B. Fonseca, D. J. Rouse, E. A. Thom, C. Y. Spong, et al.
Progesterone and Preterm Birth
N. Engl. J. Med., November 29, 2007; 357(22): 2306 - 2307.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Obstetricians and Gynecologists.